USPSTF Recommendation Statement on Hormone Therapy for Prevention of Postmenopausal Conditions

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 1, 2022

Media advisory: To contact the U.S. Preventive Services Task Force, email the Media Coordinator at Newsroom@USPSTF.net or call 301-951-9203. The full report and related articles are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time and all USPSTF articles remain free indefinitely https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.18625?guestAccessKey=4927b8e8-df65-4c08-a3e1-7c0d5ab6b4ee&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110122

 

Bottom Line: The U.S. Preventive Services Task Force (USPSTF) recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons and against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy. This recommendation applies to asymptomatic, postmenopausal persons who are considering hormone therapy for the primary prevention of chronic medical conditions. The prevalence and incidence of most chronic diseases (such as cardiovascular disease, cancer, osteoporosis, and fracture) increase with age, and U.S. persons who reach menopause are expected on average to live more than another 30 years. However, the excess risk for chronic conditions that can be attributed to menopause alone is uncertain. The USPSTF routinely makes recommendations about the effectiveness of preventive care services and this recommendation is consistent with its 2017 statement on hormone therapy for the primary prevention of chronic conditions in postmenopausal women.

 

(doi:10.1001/jama.2022.18625)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Note: More information about the U.S. Preventive Services Task Force, its process, and its recommendations can be found on the newsroom page of its website.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.